阿尔茨海默病诊断范式的转变

doi:10.3969/j.issn.1672-6731.2026.02.001

中国现代神经疾病杂志 ›› 2026, Vol. 26 ›› Issue (2): 105-108. doi: 10.3969/j.issn.1672-6731.2026.02.001

• 专论 • 上一篇

2 阿尔茨海默病诊断范式的转变

纪勇, 王盼

300350 天津市环湖医院神经内科

收稿日期:2026-02-22 发布日期:2026-03-12
通讯作者: 王盼，Email:wpaofeier@163.com
基金资助:
国家自然科学基金资助项目(项目编号:82501455);天津市科技重大专项与工程(项目编号:24ZXGQSY00070);天津市自然科学基金资助项目(项目编号:25JCLMJC00070);天津市教委科研计划项目(项目编号:2024ZD060);天津市教委科研计划项目(项目编号:2023KJ060);天津市卫生健康科技项目(项目编号:TJWJ2023QN060);天津市医学重点学科(专科)建设项目(项目编号:TJYXZDXK-3-014B)

The paradigm shift in the diagnosis of Alzheimer's disease

JI Yong, WANG Pan

Department of Neurology, Tianjin Huanhu Hospital, Tianjin 300350, China

Received:2026-02-22 Published:2026-03-12
Supported by:
This study was supported by the National Natural Science Foundation of China (No. 82501455);Major Science and Technology Special Projects and Engineering of Tianjin (No. 24ZXGQSY00070);Tianjin Natural Science Foundation (No. 25JCLMJC00070);Tianjin Municipal Education Commission Scientific Research Program (No. 2024ZD060, 2023KJ060);Tianjin Health Research Project (No. TJWJ2023QN060);Tianjin Key Medical Discipline (Specialty) Construction Project (No. TJYXZDXK-3-014B)

摘要/Abstract

摘要： 阿尔茨海默病的诊断标准业已发生根本性转变，实现从临床症状到精准病理变化的重心转移。本文聚焦阿尔茨海默病脑脊液标志物、血液标志物、分子影像学标志物的诊断进展及未来展望，以期对疾病的早期精准诊断提供指导。

关键词: 阿尔茨海默病, 淀粉样β肽类, tau蛋白质类, 正电子发射断层显像术, 综述

Abstract: The diagnostic criteria for Alzheimer's disease(AD) has undergone the fundamental shift, moving from clinical symptom-based approach to the focus on precise pathological changes. This paper focuses on the diagnostic advances and future prospects of cerebrospinal fluid biomarkers, blood biomarkers, and molecular imaging biomarkers for Alzheimer's disease, aiming to provide guidance for the early and accurate diagnosis of the disease.

Key words: Alzheimer disease, Amyloid beta-peptides, Tau proteins, Positron-emission tomography, Review

中图分类号:

R741

纪勇, 王盼. 阿尔茨海默病诊断范式的转变[J]. 中国现代神经疾病杂志, 2026, 26(2): 105-108.

JI Yong, WANG Pan. The paradigm shift in the diagnosis of Alzheimer's disease[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2026, 26(2): 105-108.

https://journal11.magtechjournal.com/cjcnn/CN/Y2026/V26/I2/105

参考文献

[1] Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, Kirabali T, Krolak-Salmon P, Rossini PM, Ferretti MT, Lanman L, Chadha AS, van der Flier WM.Global estimates on the number of persons across the Alzheimer's disease continuum[J]. Alzheimers Dement, 2023, 19:658-670.
[2] Gan J, Zeng Y, Huang G, Wang XD, LüY, Niu J, Meng X, Cai P, Li X, Li Y, Shen L, You Y, Gang B, Tang Y, Lv Y, Ren Z, Liu S, Ji Y.The updated prevalence and risk factors of dementia in old adults in China:a cross-sectional study[J]. JAlzheimers Dis, 2024, 102:1209-1223.
[3] Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC.Revised criteria for diagnosis and staging of Alzheimer's disease:Alzheimer's Association Workgroup[J]. Alzheimers Dement, 2024, 20:5143-5169.
[4] Barthélemy NR, Bateman RJ, Hirtz C, Marin P, Becher F, Sato C, Gabelle A, Lehmann S.Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification[J]. Alzheimers Res Ther, 2020, 12:26.
[5] Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H, Scheffler M, Assal F, Garibotto V, Blennow K, Hansson O, Frisoni GB.Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus ptau181 and p-tau231 in a memory clinic cohort[J]. J Neurol, 2024, 271:2053-2066.
[6] Amft M, Ortner M, Eichenlaub U, Goldhardt O, Diehl-Schmid J, Hedderich DM, Yakushev I, Grimmer T.The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort[J]. Alzheimers Res Ther, 2022, 14:60.
[7] Pahlke S, Kahale LA, Mahinrad S, Sousa-Pinto B, Vieira RJ, McAteer MB, Claessen T, Contador J, Hofmann A, Kuchenbecker LA, Machado LS, Warmenhoven N, Yakoub Y, Palmqvist S, Schindler SE, Teunissen C, Whitson HE, Zetterberg H, Edelmayer R, Tampi MP.Blood-based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings:a systematic review and meta-analysis[J]. Alzheimers Dement, 2025, 21:e70828.
[8] Catania M, Battipaglia C, Perego A, Salvi E, Maderna E, Cazzaniga FA, Rossini PM, Marra C, Vanacore N, Redolfi A, Perani D, Spadin P, Cotelli M, Cappa S, Caraglia N, Tiraboschi P, Tagliavini F, Di Fede G.Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of mild cognitive impairment by the fully automated Lumipulse^®platform[J]. Fluids Barriers CNS, 2025, 22:9.
[9] Warmenhoven N, SalvadóG, Janelidze S, Mattsson-Carlgren N, Bali D, Orduña Dolado A, Kolb H, Triana-Baltzer G, Barthélemy NR, Schindler SE, Aschenbrenner AJ, Raji CA, Benzinger TLS, Morris JC, Ibanez L, Timsina J, Cruchaga C, Bateman RJ, Ashton N, Arslan B, Zetterberg H, Blennow K, Pichet Binette A, Hansson O.A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests[J]. Brain, 2025, 148:416-431.
[10] Aarsland D, Sunde AL, Tovar-Rios DA, Leuzy A, Fladby T, Zetterberg H, Blennow K, Tan K, De Santis G, Yakoub Y, Arslan B, Huber H, Pola I, Grötschel L, Di Molfetta G, Skjellegrind HK, Selbaek G, Ashton NJ.Prevalence of Alzheimer's disease pathology in the community[J]. Nature, 2026, 650:182-186.
[11] Barthélemy NR, SalvadóG, Schindler SE, He Y, Janelidze S, Collij LE, Saef B, Henson RL, Chen CD, Gordon BA, Li Y, La Joie R, Benzinger TLS, Morris JC, Mattsson-Carlgren N, Palmqvist S, Ossenkoppele R, Rabinovici GD, Stomrud E, Bateman RJ, Hansson O.Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests[J]. Nat Med, 2024, 30:1085-1095.
[12] Janelidze S, Barthélemy NR, SalvadóG, Schindler SE, Palmqvist S, Mattsson-Carlgren N, Braunstein JB, Ovod V, Bollinger JG, He Y, Li Y, Raji CA, Morris JC, Holtzman DM, Ashton NJ, Blennow K, Stomrud E, Bateman RJ, Hansson O.Plasma phosphorylated tau 217 and Aβ42/40 to predict early brain Aβ accumulation in people without cognitive impairment[J]. JAMA Neurol, 2024, 81:947-957.
[13] Palmqvist S, Whitson HE, Allen LA, Suarez-Calvet M, Galasko D, Karikari TK, Okrahvi HR, Paczynski M, Schindler SE, Teunissen CE, Zetterberg H, Carrillo MC, Edelmayer RM, Mahinrad S, McAteer MB, Kahale LA, Pahlke S, Tampi MP.Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings[J]. Alzheimers Dement, 2025, 21:e70535.
[14] Frisoni GB, Hansson O, Nichols E, Garibotto V, Schindler SE, van der Flier WM, Jessen F, Villain N, Arenaza-Urquijo EM, Crivelli L, Fortea J, Grinberg LT, Ismail Z, Minoshima S, Ossenkoppele R, Zetterberg H, Petersen RC, Dubois B.New landscape of the diagnosis of Alzheimer's disease[J]. Lancet, 2025, 406:1389-1407.
[15] Reiman EM, Alexander RC, Langbaum JB, Aisen PS, Ashton N, Atri A, Barbarino P, Byrd GS, Feldman HH, Fowler NR, Ghisays V, Grill JD, Hassenstab J, Heaton GR, Herring WL, Jack CR Jr, Johnson SC, Karlawish J, Keach NL, Kivipelto M, Krumholz HM, Largent EA, MaGee-Rodgers T, McDade E, Mielke MM, Molina-Henry D, Petersen RC, Rabinovici GD, Ritchie C, Schindler SE, Sperling RA, Suárez-Calvet M, Vradenburg G, Weiner MW, Welsh-Bohmer KA, Zetterberg H, Zuendel MT, Mattke S, Cummings JL.A path to preventing cognitive impairment due to Alzheimer's disease:initiatives beginning in the USA[J]. Lancet Neurol, 2026, 25:268-278.
[16] Karur P, Kaldas M, Ramesh Babu YS, Parmar MS.Phosphorylated tau biomarkers in Alzheimer's disease:from early detection to clinical potential.A comprehensive review[J]. Mol Neurobiol, 2026, 63:389.
[17] Groot C, Smith R, Collij LE, Mastenbroek SE, Stomrud E, Binette AP, Leuzy A, Palmqvist S, Mattsson-Carlgren N, Strandberg O, Cho H, Lyoo CH, Frisoni GB, Peretti DE, Garibotto V, La Joie R, Soleimani-Meigooni DN, Rabinovici G, Ossenkoppele R, Hansson O.Tau positron emission tomography for predicting dementia in individuals with mild cognitive impairmen[tJ]. JAMA Neurol, 2024, 81:845-856.
[18] Ioannou K, Bucci M, Tzortzakakis A, Savitcheva I, Nordberg A, Chiotis K;Alzheimer's Disease Neuroimaging Initiative.Tau PET positivity predicts clinically relevant cognitive decline driven by Alzheimer's disease compared to comorbid cases;proof of concept in the ADNI study[J]. Mol Psychiatry, 2025, 30:587-599.
[19] Tang Y, Xiong X, Tong G, Yang Y, Zhang H.Multimodal diagnosis model of Alzheimer's disease based on improved transforme[rJ]. Biomed Eng Online, 2024, 23:8.
[20] Zheng X, Worhunsky P, Liu Q, Guo X, Chen X, Sun H, Zhang J, Toyonaga T, Mecca AP, O'Dell RS, van Dyck CH, Angarita GA, Cosgrove K, D'Souza D, Matuskey D, Esterlis I, Carson RE, Radhakrishnan R, Liu C.Generating synthetic brain PETimages of synaptic density based on MR T1 images using deep learning[J]. EJNMMI Phys, 2025, 12:30.
[21] Rikken RM, Yaqub M, Coomans EM, Dicks E, van der Vlies AE, Windhorst AD, Boellaard R, Pijnenburg YAL, Vijverberg EGB, van de Giessen E.Neuroinflammation PET and long-term cognition and survival in symptomatic Alzheimer's disease[J]. Alzheimers Res Ther, 2025, 17:275.
[22] Zetterberg H, Bendlin BB.Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias[J]. Nature, 2026, 650:49-59.
[23] Li D, Liu K, Li D, Brunger A, Liu C, BurréJ, Diao J.α-synuclein condensation in synaptic vesicle function and synucleinopathies[J]. Trends Cell Biol, 2026, 36:57-70.

选择文件类型/文献管理软件名称

选择包含的内容

2 阿尔茨海默病诊断范式的转变

The paradigm shift in the diagnosis of Alzheimer's disease

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	明东. 神经调控医工融合创新研究[J]. 中国现代神经疾病杂志, 2026, 26(1): 8-12.
[2]	支迪暄, 金磊, 王逸鹤, 单永治. 脑机接口临床实践与展望[J]. 中国现代神经疾病杂志, 2026, 26(1): 13-20.
[3]	杨艺, 何蕲恒, 柴晓珂, 赵继宗. 慢性意识障碍与脑机接口：神经调控医工融合新范式[J]. 中国现代神经疾病杂志, 2026, 26(1): 21-29.
[4]	靳卓, 任小欣, 王浩婷, 乔羿静, 赵玉超, 郑晨光. 非侵入性电磁神经调控治疗创伤后应激障碍认知损害研究进展[J]. 中国现代神经疾病杂志, 2026, 26(1): 30-39.
[5]	王承恩, 李雪辉, 耿子涵, 赵飞, 杨佳佳. 神经调控治疗脊髓小脑性共济失调3型临床进展[J]. 中国现代神经疾病杂志, 2026, 26(1): 40-49.
[6]	平安, 朱君明. 神经调控治疗药物难治性癫痫：从开环到闭环刺激[J]. 中国现代神经疾病杂志, 2026, 26(1): 50-56.
[7]	胡天棋, 解虎涛, 张建国. 脑深部电刺激术治疗药物难治性癫痫进展与展望[J]. 中国现代神经疾病杂志, 2026, 26(1): 57-64.
[8]	魏新明, 冯珂珂. 脑深部电刺激术在脑卒中后运动功能障碍中应用进展[J]. 中国现代神经疾病杂志, 2026, 26(1): 65-68.
[9]	吴静超, 梁思泉. 脑深部电刺激术在难治性精神疾病中应用进展[J]. 中国现代神经疾病杂志, 2026, 26(1): 69-76.
[10]	张昀昇, 王琦, 杨文强, 于炎冰, 张黎. 脊髓电刺激术临床应用进展[J]. 中国现代神经疾病杂志, 2026, 26(1): 77-84.
[11]	冯善刚, 史烨童, 尹绍雅. 迷走神经刺激术临床应用现状[J]. 中国现代神经疾病杂志, 2026, 26(1): 85-91.
[12]	杨鑫, 王书哲, 李申. 经颅交流电刺激治疗抑郁症机制研究与应用进展[J]. 中国现代神经疾病杂志, 2026, 26(1): 92-98.
[13]	邱炳辉, 杜佳澍, 钟晴蕾, 卓杰, 何山. 应重视下丘脑垂体功能障碍对重型颅脑创伤患者长期预后的影响[J]. 中国现代神经疾病杂志, 2025, 25(9): 779-783.
[14]	韩佳良, 张国斌. 小胶质细胞在颅脑创伤发病机制中的作用[J]. 中国现代神经疾病杂志, 2025, 25(9): 784-789.
[15]	潘景锡, 李文福, JalalKhan, 杜佳澍, 钟晴蕾, 包贇. 创伤性脑水肿病理学特征与治疗进展[J]. 中国现代神经疾病杂志, 2025, 25(9): 790-797.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 阿尔茨海默病诊断范式的转变

The paradigm shift in the diagnosis of Alzheimer's disease

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价